The Serum Institute of India (SII)’s vaccine Cervavac recently received the Drugs Controller General of India’s (DGCI) approval for market authorisation. Cervavac is India’s first quadrivalent human papillomavirus vaccine (qHPV) vaccine, and intended to protect women against cervical cancer.
Experts see this as a real opportunity to eliminate cervical cancer, and have expressed the hope that it will be rolled out in national HPV vaccination strategies, and be available a cost more affordable than existing vaccines.
#hpv #Vaccine #Cervicalcancer #SII #DGCI
Dear Learner ??,
Unacademy gets you,
???? Combo Festival Offer
15% off on combo subscriptions
Plus Combo : UPSC CSE GS (Plus) + UPSC CSE Optional (Plus)
[ Ссылка ]
Iconic Combo : UPSC CSE GS (Iconic) + UPSC CSE Optional (Plus)
[ Ссылка ]
???? Mains and Optional Test Series 2022
Enrollment link Mains Test Series : [ Ссылка ]
Enrollment link Optional Test Series: [ Ссылка ]
Lets Crack it ??
